Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Skin Neoplasms × Imiquimod × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Keratosis, Actinic 5 Uterine Cervical Neoplasms 3 Uterine Cervical Dysplasia 2 Papillomavirus Infections 2 Melanoma 2 Hemangioma, Capillary 2 Breast Neoplasms 2 Vulvar Neoplasms 1 Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) 1 Virus Diseases 1 Vaginal Neoplasms 1 Urinary Bladder Neoplasms 1 Skin Neoplasms 1 Sexually Transmitted Diseases 1 Precancerous Conditions 1 Pigmentation Disorders 1 Ovarian Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hemangioma 1 HPV 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Condylomata Acuminata 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Basal Cell 1 Carcinoma in Situ 1

Interventions

aldesleukin 15 Cyclophosphamide 13 fludarabine phosphate 10 fludarabine 10 Interleukin-2 10 Nivolumab 7 pembrolizumab 5 Ipilimumab 5 cemiplimab 4 Fluorouracil 4 Aminolevulinic Acid 4 sonidegib 3 Temozolomide 3 Surgical Procedures, Operative 3 Radiotherapy 3 zanolimumab 2 trametinib 2 talabostat 2 montanide ISA 51 2 dabrafenib 2 Whole-Body Irradiation 2 Tablets 2 Semaxinib 2 Radiation 2 Petrolatum 2 Peptides 2 Gefitinib 2 Cisplatin 2 Cetuximab 2 Capecitabine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03534947 2025-12-16

SONIB

Melanoma Institute Australia

Phase 2 Completed

Carcinoma, Basal Cell, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡